Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Venclexta | Venetoclax | Chronic Lymphocytic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Venclexta in combo Rituximab | Venetoclax | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Venclexta | venetoclax | Acute myeloid leukemia | Do not reimburse | Complete | ||
Venclexta | venetoclax | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Venclexta | venetoclax | Chronic lymphocytic leukemia (CLL). | Pending | |||
Venclexta | Venetoclax | Withdrawn | ||||
Venclexta | Venetoclax Obinutuzumab | Obinutuzumab for CLL | Reimburse with clinical criteria and/or conditions | Complete | ||
Verquvo | vericiguat | Heart failure | Reimburse with clinical criteria and/or conditions | Complete | ||
Viibryd | vilazodone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
Erivedge | Vismodegib | Basal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete |